Angus Dalgleish

Professor Angus Dalgleish is the principal of Cancer Vaccine Institute and studied medicine at University College London where he obtained an MBBS and a BSc in Anatomy. He is a Fellow of The Royal College of Physicians of the UK and Australia, Royal College of Pathologists and The Academy of Medical Scientists. After graduating and house jobs in London and Poole he spent a year in the flying doctor service in Queensland. He also trained in Internal Medicine and Oncology in Brisbane and Sydney, Following an interest in how viruses caused cancer, he commenced an MD with Professor Robin Weiss, FRS at the Institute of Cancer Research and Royal Marsden Hospital. Following five years as a clinical scientist at the MRC’s clinical research centre in Northwick Park, he was appointed to the Foundation Chair in Oncology at St. George’s University of London in 1991. There his main interest has been the immunology of cancer and the development of immunotherapies to treat, in particular, melanoma. He is a co-founder of Onyvax, a company set up in 1998 to make novel vaccines for common solid tumours, where he is currently Research Director.

He currently sits on eight editorial boards, is the author or co-author of peer reviewed scientific papers and over 70 chapters in medical books. He is the co-editor of five medical books. He has been on numerous grant committees and is currently on the European Commission Cancer Board.

Magnus Essand

Immunicum currently collaborates with professor Magnus Essand on the CD70-concept.

Professor Magnus Essand heads a research group at Uppsala University working with gene and immunotherapy of cancer. The team develops genetically engineered viruses and T cells as novel cancer therapeutics. The focus is on prostate cancer and various neuroendocrine tumors. To read more about Magnus work please see here.

Gunnar Kvalheim

Gunnar Kvalheim works as head of the Laboratory for Cell Therapy at Radiumhospitalet in Norway and currently holds a position as board member and advisor for the European International Society for Cellular Therapy. In addition, he is the technical advisor of Aastrom Bioscience Inc. and co-editor for the scientific magazine Cytotherapy. Gunnar has over 80 published articles and was previously vice president of the International Society of Hematology and Graft Engineering.

Gustav Gaudernack

Gustav Gaudernack works as head of the Laboratory for Immune Therapy at Radiumhospitalet and has three granted patents on peptides for the stimulation of T-lymphocytes in treatment of cancer patients or Alzheimer's disease. He has collaboration projects with Affitech AS and has published over 156 articles.